GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma Trading AD (XBUL:SFT) » Definitions » Altman Z-Score

Sopharma Trading AD (XBUL:SFT) Altman Z-Score : 2.96 (As of Jun. 29, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Sopharma Trading AD Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.96 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

Sopharma Trading AD has a Altman Z-Score of 2.96, indicating it is in Grey Zones. This implies that Sopharma Trading AD is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Sopharma Trading AD's Altman Z-Score or its related term are showing as below:

XBUL:SFT' s Altman Z-Score Range Over the Past 10 Years
Min: 2.15   Med: 2.63   Max: 3.34
Current: 2.96

During the past 13 years, Sopharma Trading AD's highest Altman Z-Score was 3.34. The lowest was 2.15. And the median was 2.63.


Sopharma Trading AD Altman Z-Score Historical Data

The historical data trend for Sopharma Trading AD's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma Trading AD Altman Z-Score Chart

Sopharma Trading AD Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 2.56 2.97 3.13 2.96

Sopharma Trading AD Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 2.98 2.94 2.77 2.96

Competitive Comparison of Sopharma Trading AD's Altman Z-Score

For the Medical Distribution subindustry, Sopharma Trading AD's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma Trading AD's Altman Z-Score Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Sopharma Trading AD's Altman Z-Score falls into.


;
;

Sopharma Trading AD Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Sopharma Trading AD's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1047+1.4*-0.0037+3.3*0.0707+0.6*0.3115+1.0*2.4191
=2.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2024:
Total Assets was лв803 Mil.
Total Current Assets was лв597 Mil.
Total Current Liabilities was лв513 Mil.
Retained Earnings was лв-3 Mil.
Pre-Tax Income was 12.242 + 8.771 + 11.536 + 14.458 = лв47 Mil.
Interest Expense was -2.627 + -2.697 + -2.25 + -2.187 = лв-10 Mil.
Revenue was 541.981 + 487.612 + 446.903 + 465.346 = лв1,942 Mil.
Market Cap (Today) was лв199 Mil.
Total Liabilities was лв638 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(596.946 - 512.929)/802.726
=0.1047

X2=Retained Earnings/Total Assets
=-3.006/802.726
=-0.0037

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(47.007 - -9.761)/802.726
=0.0707

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=198.801/638.215
=0.3115

X5=Revenue/Total Assets
=1941.842/802.726
=2.4191

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Sopharma Trading AD has a Altman Z-Score of 2.96 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Sopharma Trading AD  (XBUL:SFT) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Sopharma Trading AD Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Sopharma Trading AD's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sopharma Trading AD Business Description

Traded in Other Exchanges
N/A
Address
Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.

Sopharma Trading AD Headlines

No Headlines